NCCN revises hepatobiliary cancer guide
NCCN updates hepatobiliary cancer treatment guidelines.
Sorafenib (Nexavar, Bayer Healthcare/Onyx) is now included as a treatment option for patients with hepatocellular carcinoma (HCC). So say the newly revised treatment guidelines for hepatobiliary cancers from the National Comprehensive Cancer Network (NCCN). Specifically, sorafenib is recommended for patients with HCC who have unresectable disease or decline surgery. Supporting this change were results from the Sorafenib HCC Assessment Randomized Protocol (SHARP) phase III trial that showed overall survival was extended by 44% in patients with advanced HCC who received sorafenib compared with placebo. Sorafenib is only for patients with Child-Pugh class A liver function status, and the therapy is not recommended for patients potentially eligible for liver transplant since the impact of the drug is this population is unknown. The updated guide can be accessed at www.nccn.org.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
